105
Participants
Start Date
February 19, 2025
Primary Completion Date
June 1, 2026
Study Completion Date
September 1, 2026
Varenicline Pill
In this study, all participants will be administered active medication for a 12 week treatment period. The standard dose titration schedule will be used, which includes 0.5 mg once per day (q.d.) on Days 1-3, 0.5 mg twice per day (b.i.d.) on Days 4-7, and 1.0 mg b.i.d. starting on Day 8. Dosing of 2.0 mg per day will be maintained for the next 11 weeks, for a total of 12 weeks of active treatment for all study participants.
Contingency management
Contingency management procedures will be implemented and financial incentives will be provided at weekly visits contingent on e-cigarette abstinence verified through urinary qualitative cotinine (starting at Week 2). A set amount of $20 per study visit will be delivered based on a negative qualitative urinary cotinine result.
Counseling
Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study.
RECRUITING
MUSC Charleston, Charleston
RECRUITING
Behavioral Health Services of Pickens County, Pickens
RECRUITING
MUSC Lancaster, Lancaster
National Cancer Institute (NCI)
NIH
Medical University of South Carolina
OTHER